4basebio (LON:4BB) Stock Price Down 1.4% – What’s Next?

4basebio PLC (LON:4BB)’s share price fell 1.4% during mid-day trading on Monday . The stock traded as low as GBX 501.63 and last traded at GBX 501.63. 2,809 shares changed hands during mid-day trading, an increase of 75% from the average session volume of 1,606 shares. The stock had previously closed at GBX 508.80.

4basebio Trading Down 1.4%

The company has a market cap of £77.68 million, a price-to-earnings ratio of -5.07 and a beta of 1.09. The company has a debt-to-equity ratio of 201.47, a quick ratio of 3.52 and a current ratio of 2.73. The business’s 50 day moving average price is GBX 569.90 and its 200-day moving average price is GBX 687.73.

Insider Activity

In other 4basebio news, insider Hansjörg Plaggemars purchased 1,000 shares of the business’s stock in a transaction on Tuesday, February 10th. The stock was purchased at an average price of GBX 585 per share, for a total transaction of £5,850. Also, insider Heikki Lanckriet purchased 3,000 shares of the business’s stock in a transaction on Tuesday, February 10th. The shares were acquired at an average price of GBX 576 per share, with a total value of £17,280. In the last three months, insiders have acquired 6,650 shares of company stock worth $3,865,900. Corporate insiders own 12.07% of the company’s stock.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.